ANDAINJECTIONINJECTABLE
Approved
Oct 2021
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
8
Mechanism of Action
understood. Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein promyelocytic leukemia (PML)-retinoic acid receptor (RAR)-alpha.
Indications (1)
Clinical Trials (5)
Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)
Started Sep 2011
7 enrolled
Chronic Myelogenous Leukemia
Study of Arsenic Trioxide in Small Cell Lung Cancer
Started Aug 2011
20 enrolled
Lung CancerCancer of LungPulmonary Cancer+2 more
Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome
Started Nov 2007
7 enrolled
Myelodysplastic Syndrome
Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia
Started Oct 2007
67 enrolled
Acute Myeloid Leukemia
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
Started Feb 2007
1 enrolled
LeukemiaMyelodysplastic Syndromes